Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 15, 2020 (6 years ago)

Estriol USP Micronized 5 G

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed impurities/ degradation specifications: Out of specification for organic impurities.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Estriol USP Micronized 5 G, Rx only, Triova 115 W 3rd Street Suite 720 Tulsa, OK 74103, NDC 71092-9977-02

Affected NDC 71092-9977-02

Compare with the code on your package — it is the most precise check available.

Drug: Estriol

Recalling firm
Triova Pharmaceuticals LLC
NDC code
71092-9977-02
Origin
OK, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1284-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Estriol recalls

See all
Class II · Moderate risk

Estriol 1mg/gm

Lack of Processing Controls: Insanitary conditions observed during recent FDA Inspection

Terminated cGMP deviation Wedgewood Village Pharmacy, LLC D-1186-2022
Class II · Moderate risk

Estriol 1mg/gm

Lack of Processing Controls: Insanitary conditions observed during recent FDA Inspection

Terminated cGMP deviation Wedgewood Village Pharmacy, LLC D-1185-2022
Class II · Moderate risk

Estriol 8 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1421-2020
Class II · Moderate risk

Estriol 6 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1420-2020

Other impurity / degradation recalls from 2020

All impurity / degradation recalls
Class III · Low risk

Benzhydrocodone and Acetaminophen Tablets

Failed Impurities/Degradation Specifications; out of specification results obtained for N-Oxide impurity during the 12-month long term stability testing for Batch# 15892A

Terminated Impurity / degradation KVK-Tech, Inc. NDC 10702-344-01 D-0224-2021
Class II · Moderate risk

Hydroxyzine Hydrochloride Oral Solution

Failed Impurities/Degradation Specification: OOS for the following - unknown degradant/impurity, 4-chorobenzophenone, and for total impurities.

Terminated Impurity / degradation Morton Grove Pharmaceuticals, Inc. NDC 60432-150-04 D-0174-2021